Isavuconazole is a newer triazole approved for invasive aspergillosis and mucormycosis. Compared to voriconazole, its pharmacological advantages include:
- A Superior Aspergillus coverage at lower MICs, the ability to be used in renal failure without nephrotoxicity concerns, and fewer hepatic cytochrome interactions
- B Activity against Candida glabrata with azole resistance due to FKS mutations, unlike voriconazole
- C Linear pharmacokinetics (no CYP2C19 polymorphism effect), no QTc prolongation, coverage of Mucorales, and better tolerability without phototoxicity or periostitis ✓
- D Prodrug formulation allowing intramuscular injection avoiding cyclodextrin vehicle-related nephrotoxicity seen with IV voriconazole
Explanation
Isavuconazole (administered as its water-soluble prodrug isavuconazonium sulfate) offers several advantages: (1) Linear, predictable pharmacokinetics without the CYP2C19 polymorphism-dependent variability that makes voriconazole levels difficult to predict; (2) No QTc prolongation (voriconazole has a small QTc prolongation risk; isavuconazole may even shorten QTc slightly); (3) Extended spectrum against Mucorales (zygomycetes), unlike voriconazole which lacks Mucorales activity; (4) No phototoxicity, periostitis with long-term use, or fluoride accumulation. The IV formulation does not use nephrotoxic cyclodextrin vehicle (unlike IV voriconazole with SBECD), making it safe in renal impairment.
Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.